ARCH THERAPEUTICS, INC. (OTCMKTS:ARTH) Files An 8-K Regulation FD Disclosure
Item 7.01
On August 5, 2019, Arch Therapeutics, Inc. (the “Company”) issued a press release that announced the results of two studies conducted to assess the antimicrobial properties of the Company’s AC5TM self-assembling peptide technology platform (AC5), and provided an update on the status of the Company’s application for a CE Mark for its AC5 Topical Hemostat product. The text of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
The disclosure under Item 7.01 (Regulation FD Disclosure) is incorporated herein by reference.
(d) The following exhibits are being filed herewith:
| 99.1 | Press Release issued by Arch Therapeutics, Inc. on August 5, 2019 |
Arch Therapeutics, Inc. Exhibit
EX-99.1 2 tv526725_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Arch Therapeutics Announces AC5 Self-Assembling Peptide Technology Platform Demonstrates Antimicrobial Activity in Two Studies and Provides CE Marking Status Update for AC5™ Topical Hemostat Studies highlight antimicrobial activity for AC5 technology platform; AC5™ Topical Hemostat1 under Review by Notified Body FRAMINGHAM,…
To view the full exhibit click here
About ARCH THERAPEUTICS, INC. (OTCMKTS:ARTH)
Arch Therapeutics, Inc. is a development-stage company. The Company operates as a biotechnology company. The Company focuses on developing products to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. The Company’s technology is based on a self-assembling peptide that creates a physical, mechanical barrier, which could be applied to seal organs or wounds that are leaking blood and other fluids. The Company’s primary product candidates, collectively known as the AC5 Devices (AC5), are designed to achieve hemostasis in surgical procedures. The Company’s product candidates rely on its self-assembling peptide technology and are designed to achieve hemostasis in skin wounds, and minimally invasive and open surgical procedures. The Company focuses on developing other product candidates based on its technology platform for use in a range of indications. As of September 30, 2016, the Company had not generated any revenues.
